The Claim
In adolescents with obesity and type 2 diabetes, 36 weeks of weekly Mazdutide 6 mg combined with metformin and insulin was associated with a 21.88% reduction in HbA1c from 9.60% to 7.50%, with no episodes of hypoglycemia reported.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adolescents with obesity and type 2 diabetes, treatment with weekly Mazdutide 6 mg along with metformin and insulin for 36 weeks resulted in a 21.88% decrease in HbA1c from 9.60% to 7.50%, with no hypoglycemic episodes.
See the scientific wording
In an adolescent with obesity and type 2 diabetes, 36 weeks of weekly Mazdutide 6 mg combined with metformin and insulin was associated with a 21.88% reduction in HbA1c from 9.60% to 7.50%, with no episodes of hypoglycemia reported.
A drug that activates two receptors in the body causes the pancreas to release more insulin only when blood sugar is high, while also forcing the liver to burn fat for energy instead of storing it. This reduces excess sugar in the blood and clears fat from the liver, leading to lower blood sugar levels without causing dangerously low blood sugar.
What the research says
1 studyA teen with obesity and diabetes got a weekly shot called Mazdutide along with his usual diabetes pills and insulin. After 36 weeks, his blood sugar dropped by nearly 22% — and he never had dangerously low blood sugar.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.